Western blot analysis of tumor tissues confirmed that fedratinib downregulated key signaling molecules and effector proteins, including JAK2, p-JAK2, STAT3, p-STAT3, vimentin, survivin, and cyclin D1 (Figure 6E). The gene discussed is BIRC5; the disease is neoplasm.